CME webinar series: Empowering Providers on Substance Use Disorders

Jun. 2025Education/Webinars

Register for our new CME webinar series: Empowering Providers on Substance Use Disorders

Join us for our upcoming CME webinar series, "Empowering Providers," designed to enhance your knowledge and skills in managing substance use disorders. This four-part series will provide you with the latest insights and evidence-based strategies to improve patient outcomes.

Overdose Prevention and Response Training

  • Join us on Aug. 26, 2025, from noon to 1 p.m., to learn how to recognize overdose risks and symptoms, respond effectively, and apply proven strategies to prevent patient overdose.

    Comprehensive Care for Alcohol Use Disorder

  • Join us on Sept. 9, 2025, from noon to 1 p.m., to explore the importance of screening for alcohol use disorder (AUD), learn how to use effective screening tools, and apply evidence-based treatment strategies to improve patient care.

    Comprehensive Care for Opioid Use Disorder

  • Join us on Sept. 30, 2025, from noon to 1 p.m., to explore the importance of screening for opioid use disorder (OUD), learn how to use effective screening tools, and implement evidence-based treatments to support recovery.

    Comprehensive Care for Tobacco Use Disorder

  • Join us on Nov. 12, 2025, from noon to 1 p.m., to learn how to recognize tobacco use disorder (TUD), use proven screening tools, and deliver evidence-based care to help patients quit tobacco successfully.

Register Now

Provider is responsible for verifying CME eligibility.

This activity is approved for the following credit: AMA PRA Category 1 Credit™, ANCC, ACPE, and ASWB. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.


Recent Announcements

October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.
Oct. 2025Pharmacy Updates

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates

HelpScript service helps patients enroll in manufacturer copay assistance programs

End-to-end provider support helps ensure a smooth submission process
Oct. 2025Important Notices